Quince Therapeutics Statistics
Total Valuation
QNCX has a market cap or net worth of $7.85 million. The enterprise value is $8.46 million.
Important Dates
The last earnings date was Friday, April 10, 2026, after market close.
| Earnings Date | Apr 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
QNCX has 5.57 million shares outstanding. The number of shares has increased by 15.80% in one year.
| Current Share Class | 5.57M |
| Shares Outstanding | 5.57M |
| Shares Change (YoY) | +15.80% |
| Shares Change (QoQ) | +3.21% |
| Owned by Insiders (%) | 106.33% |
| Owned by Institutions (%) | 487.73% |
| Float | 49.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.53
| Current Ratio | 0.53 |
| Quick Ratio | 0.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -55.17 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -30.31% |
| Return on Invested Capital (ROIC) | -228.40% |
| Return on Capital Employed (ROCE) | -100.26% |
| Weighted Average Cost of Capital (WACC) | 6.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.33M |
| Employee Count | 36 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QNCX has paid $3.21 million in taxes.
| Income Tax | 3.21M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.90% in the last 52 weeks. The beta is 1.33, so QNCX's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -85.90% |
| 50-Day Moving Average | 1.44 |
| 200-Day Moving Average | 16.73 |
| Relative Strength Index (RSI) | 42.84 |
| Average Volume (20 Days) | 12,139,345 |
Short Selling Information
| Short Interest | 13.83M |
| Short Previous Month | 11.15M |
| Short % of Shares Out | n/a |
| Short % of Float | 27.79% |
| Short Ratio (days to cover) | 0.20 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -50.43M |
| Pretax Income | -80.77M |
| Net Income | -83.98M |
| EBITDA | -50.29M |
| EBIT | -50.43M |
| Earnings Per Share (EPS) | -$16.80 |
Full Income StatementBalance Sheet
The company has $17.75 million in cash and $18.36 million in debt, with a net cash position of -$604,000 or -$0.11 per share.
| Cash & Cash Equivalents | 17.75M |
| Total Debt | 18.36M |
| Net Cash | -604,000 |
| Net Cash Per Share | -$0.11 |
| Equity (Book Value) | -35.71M |
| Book Value Per Share | -6.41 |
| Working Capital | -20.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$41.43 million and capital expenditures -$352,000, giving a free cash flow of -$41.78 million.
| Operating Cash Flow | -41.43M |
| Capital Expenditures | -352,000 |
| Depreciation & Amortization | 142,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -41.78M |
| FCF Per Share | -$7.50 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
